Oyster Point Pharma has announced that its investigational new drug application for OC-01, a nicotine acetylcholine receptor (nAChR) agonist nasal spray, has been cleared by the FDA. OC-01 and another nAChR nasal spray, OC-02, are both in Phase 2 development for the treatment of dry eye disease.
The company said that an IND for OC-02 was cleared in October 2017, and a Phase 2 trial of that nasal spray was completed recently.
Oyster Point CEO Jeffrey Nau commented, “Our innovative pharmaceutical approach leverages the parasympathetic nervous system by stimulating the glands responsible for producing natural tear film. Delivered through a nasal spray, as opposed to traditional eye drops, this therapy has the potential to immediately reduce the symptoms of dry eye. Clearance of our IND application for OC-01 allows us to quickly advance this therapy into Phase 2 clinical trials. We look forward to continuing Phase 2 clinical trials for both drug candidates, OC-01 and OC-02, and sharing the results of multiple studies over the course of the year.”
Read the Oyster Point Pharma press release.
